Viewing Study NCT03964233


Ignite Creation Date: 2025-12-25 @ 2:45 AM
Ignite Modification Date: 2025-12-31 @ 1:17 PM
Study NCT ID: NCT03964233
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-09-23
First Post: 2019-05-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Sponsor: Boehringer Ingelheim
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module